Browsing Tag
Moderna
33 posts
Fall 2025 COVID booster update: FDA endorses JN.1-based vaccine as dominant LP.8.1 strain spreads
FDA backs fall 2025 COVID booster targeting LP.8.1; rollout to begin by August. New vaccine expected to offer stronger protection against dominant variants.
May 26, 2025
Sarepta, Palantir, Moderna lead Wall Street declines as biotech, tech stocks tumble
U.S. stock market losers on May 6, 2025: Find out why Sarepta, Palantir, Moderna, Lattice Semiconductor and more saw sharp stock price drops.
May 7, 2025
US stock market declines as Vaxcyte, Biohaven, and Moderna lead losses
US stocks closed sharply lower on March 31, 2025, led by biotech and tech losses. Learn why markets are reacting to tariffs, interest rates, and economic uncertainty.
April 1, 2025
China discovers new bat coronavirus HKU5-CoV-2: How serious is the threat?
A newly identified bat coronavirus, HKU5-CoV-2, has been discovered by Chinese scientists, raising concerns about animal-to-human transmission and…
February 22, 2025
HHS invests $590m in Moderna for mRNA-based pandemic influenza vaccines
The U.S. Department of Health and Human Services (HHS) has announced a monumental $590 million investment in Moderna,…
January 20, 2025
First U.S. bird flu death sparks health concerns: What you should know
The United States has reported its first human fatality from the H5N1 avian influenza, a development raising critical…
January 7, 2025
Merck invests $50m in Personalis to bolster Moderna collaboration on individualized cancer therapies
Personalis, Inc., a leader in precision oncology solutions, has secured a significant investment from Merck and extended its…
December 19, 2024
Is US facing new COVID-19 nightmare? KP.2 variant pushes hospitalization rates to record levels
The United States is grappling with the most severe COVID-19 surge since 2022, characterised by a sharp increase…
August 17, 2024
Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada,…
December 15, 2023
Moderna, Merck get FDA breakthrough status for mRNA-4157/V940, KEYTRUDA combo in melanoma
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung…
February 23, 2023